|Mr. Lars Fruergaard JÃ¸rgensen||Pres, CEO & Member of Management Board||N/A||N/A||1966|
|Mr. Karsten Munk Knudsen||Exec. VP, CFO & Member of the Management Board||N/A||N/A||1971|
|Dr. Mads Krogsgaard Thomsen||Exec. VP, Chief Scientific Officer, Head of R&D and Member of the Management Board||N/A||N/A||1960|
|Mr. Henrik Ehlers Wulff||Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board||N/A||N/A||1970|
|Ms. Camilla Sylvest||Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board||N/A||N/A||1972|
|Ms. Monique Carter||Exec. VP, Head of People & Organisation and Member of Management Board||N/A||N/A||1973|
|Mr. Maziar Mike Doustdar||Exec. VP, Head of International Operations & Member of the Management Board||N/A||N/A||1970|
|Mr. Douglas J. Langa||Exec. VP, Head of North America Operations & Member of Management Board||N/A||N/A||1966|
|Mr. Ludovic Helfgott||Exec. VP, Head of Biopharm & Member of Management Board||N/A||N/A||1974|
|Mr. Peter Hugreffe Ankersen||Head of Investor Relations & Corp. VP||N/A||N/A||N/A|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S’s ISS Governance QualityScore as of January 22, 2021 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 10; Compensation: 1.